soul trial oral semaglutide cardiovascular outcomes 2025 New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj and (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis soul trial oral semaglutide cardiovascular

Since the onset of ASD is triggered by both genetic and environmental factors via a cascade of biochemical events that leads to pleiotropic metabolic abnormalities with high variability among the individuals, it is challenging to identify ASD biomarkers 6

This suggests the weight loss wasnt from making the mice sick or suppressing appetite, but from genuinely changing their metabolism to burn more energy

The way patients perceive changes in their treatment can have a significant impact on outcomes, as some may delay seeking medical advice or adjusting their treatment regimen without consulting a healthcare professional

Why these two get studied together The short answer is that the preclinical literature on each peptide individually points at overlapping but distinct elements of the wound-repair toolkit: BPC-157 has been associated with angiogenesis and growth-factor signaling, while thymosin beta-4 fragments have been associated with cell migration